The effect of memantine and levodopa/carbidopa on the responses of phrenic nerve-diaphragm preparations from aged rats

Medical Science Monitor

Volumn 15, Issue 11, 2009, Pages

  El Moursy, Soha A ^a   Shawky, Heba M ^a   Wahab, Zainab Abdel ^a   Rashed, Laila ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Alzheimer's dementia; Carbidopa; Junction; Levodopa; Memantine; Neuromuscular; Nicotinic acetylcholine receptors; NMDA; Parkinsonism

Indexed keywords

CARBIDOPA PLUS LEVODOPA; GALLAMINE; MEMANTINE; MESSENGER RNA; NEOSTIGMINE; NICOTINIC RECEPTOR;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAPHRAGM; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE CONTRACTION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHRENIC NERVE; POLYMERASE CHAIN REACTION; RAT; STIMULATION; TREATMENT DURATION;

AGING; ANIMALS; CARBIDOPA; DIAPHRAGM; ELECTRIC STIMULATION; GALLAMINE TRIETHIODIDE; GENE EXPRESSION REGULATION; LEVODOPA; MALE; MEMANTINE; MUSCLE CONTRACTION; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; PHRENIC NERVE; PROTEIN SUBUNITS; RATS; RECEPTORS, NICOTINIC; RNA, MESSENGER;

EID: 71649102975     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Gilling KE, Jatzke C, Parsons CG: Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine. Neuropharmacology, 2007; 53(3): 415-420 (Pubitemid 47212248)
2. Carmeli E, Reznick AZ: The physiology and biochemistry of skeletal muscle atrophy as a function of age. Proc Soc Exp Biol Med, 1994; 206(2): 103-113 (Pubitemid 24188323)
3. Enz A, Gentsch C: Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology, 2004; 47(3): 408-413
4. Wise LE, Lichtman AH: The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. Eur J Pharmacol, 2007; 575(1-3): 98-102
5. D'Amico M, Di Filippo C, Rossi F, Rossi F: Arrhythmias induced by myocardial ischaemia-reperfusion are sensitive to ionotropic excitatory amino acid receptor antagonists. Eur J Pharmacol, 1999; 366(2-3): 167-174 (Pubitemid 29080780)
6. Marin C, Aguilar E, Bonastre M: Effect of locus coeruleus denervation on LD-induced motor fluctuations in parkinsonian rats. J Neural Transm, 2008; 115(8): 1133-1139
7. Ahmed MR, Bychkov E, Gurevich VV et al: Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J Neurochem, 2008; 104(6): 1622-1636 (Pubitemid 351316768)
8. Bychkov E, Ahmed MR, Dalby KN, Gurevich EV: Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem, 2007; 102(3): 699-711 (Pubitemid 47057295)
9. Lindgren HS, Rylander D, Ohlin KE et al: The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res, 2007; 177(1): 150-159
10. Bulbring E: Observations on the isolated phrenic nerve diaphragm of the rat. Brit J Pharmacol, 1946; 1: 38-61
11. Grangeiro MS, Calheiros-Lima AP, Martins MF et al: Pharmacological effects of Eugenia punicifolia (Myrtaceae) in cholinergic nicotinic neurotransmission. J Ethnopharmacol, 2006; 108(1): 26-30
12. Prado WA, Corrado AP: Cholinergic agonist and antagonist interactions on motor nerve endings of the rat-evidence for the involvement of presynaptic receptors in the regulation of acetylcholine release. Gen Pharmacol, 1987; 18(1): 75-81
13. Bray JJ, Forrest JW, Hubbard JI: Evidence for the role of non-quantal acetylcholine in the maintenance of the membrane potential of rat skeletal muscle. J Physiol, 1982; 326: 285-296
14. Aziz L, Ono K, Ohta Y et al: Effect of hypothermia on the in vitro potencies of neuromuscular blocking agents and on their antagonism by neostigmine. Br J Anaesth, 1994; 73(5): 662-666 (Pubitemid 24323499)
15. Morè L, Gravius A, Nagel J et al: Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Behav Pharmacol, 2008; 19(7): 724-734
16. Baas H, Zehrden F, Selzer R et al: Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet, 2001; 40(5): 383-393 (Pubitemid 32565598)
17. Zhang J, Qu FR, Nakatsuka A et al: Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res, 2003; 993(1-2): 54-58 (Pubitemid 37464582)
18. Chomkczynski P, Sacchi N: Single step method for RNA isolation by the acid guanidinum thiocyanate-phenol-chloroform method. Analytical Biochemistry, 1987; 162: 156-160
19. Sven F, Tejvir S, Khurana T, Neal A: Identification of Acetylcholine Receptor Subunits Differentially Expressed in Singly and Multiply Innervated Fibers of Extraocular Muscles. Investigative Ophthalmology and Visual Science, 2006; 47: 3828-3834 (Pubitemid 46044297)
20. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev, 2003; 9(3): 275-308 (Pubitemid 37254706)
21. Robinson DM, Keating GM: Memantine: a review of its use in Alzheimer's disease. Drugs, 2006; 66(11): 1515-1534 (Pubitemid 44250755)
22. Rogawski MA: Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - toward an understanding of their favorable tolerability. Amino Acids, 2000; 19(1): 133-149
23. Tsai MC, Chen ML, Lo SC, Tsai GC: Effects of memantine on the twitch tension of mouse diaphragm. Eur J Pharmacol, 1989; 160(1): 133-140 (Pubitemid 19044837)
24. Danysz W, Parsons CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry, 2003; 18: S23-32 (Pubitemid 37150475)
25. Dale HH, Feldberg W, Vogt M: Release of acetylcholine at voluntary motor nerve endings. J Physiol, 1936; 86: 353-380
26. Malomouzh AI, Mukhtarov MR, Nikolsky EE et al: Glutamate regulation of non-quantal release of acetylcholine in the rat neuromuscular junction. J Neurochem, 2003; 85: 206-213 (Pubitemid 36389710)
27. Pinard A, Levesque S, Robitaille R: NO-dependence of glutamate-mediated synaptic depression at the frog neuromuscular junction. Soc Neurosci Abstr, 2002; 838: 836
28. Waerhaug O, Ottersen OP: Demonstration of glutamate-like immunoreactivity at rat neuromuscular junctions by quantitative electron microscopic immunocytochemistry. Anat Embryol, 1993; 188: 501-513 (Pubitemid 24000116)
29. Barthelemy-Requin M, Portalier P, Chamoin MC, Ternaux JP: Acetylcholine secretion enhanced by glutamate in rat embryonic spinal motoneurons: respective involvement of NMDA and AMPA receptors. Neurochem Res, 2000; 25: 377-384 (Pubitemid 30161484)
30. Berger UV, Carter RE, Coyle JT: The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolysing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junction. Neuroscience, 1995; 64: 847-850
31. Fu WM, Liou JC, Lee YH, Liou HC: Potentiation of neurotransmitter release by activation of presynaptic glutamate receptors at developing neuromuscular synapses of Xenopus. J Physiol, 1995; 489: 813-823
32. Chen YH, Wu ML, Fu WM: Regulation of presynaptic NMDA responses by external and intracellular pH changes at developing neuromuscular synapses. J Neurosci, 1998; 18: 2982-2990
33. Grozdanovic Z, Gossrau R: Co-localization of nitric oxide synthase I (NOS I) and NMDA receptor subunit 1 (NMDAR-1) at the neuromuscular junction in rat and mouse skeletal muscle. Cell Tissue Res, 1998; 291: 57-63
34. Liou HC, Yang RS, Fu WM: Potentiation of spontaneous acetylcholine release from motor nerve terminals by glutamate in Xenopus tadpoles. Neuroscience, 1996; 75: 325-331
35. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX: Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl- D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther, 2005; 312(3): 1195-1205 (Pubitemid 40293781)
36. Todd KJ, Slatter CA, Ali DW: Activation of ionotropic glutamate receptors on peripheral axons of primary motoneurons mediates transmitter release at the zebrafish NMJ. J Neurophysiol, 2004; 91(2): 828-840
37. Koyuncuoǧlu H, Kara I, Günel MA et al: N-methyl-D-aspartate antagonists, glutamate release inhibitors, 4-aminopyridine at neuromuscular transmission. Pharmacol Res, 1998; 37(6): 485-491
38. Di Stefano A, Sozio P, Cerasa LS: Antiparkinson prodrugs. Molecules, 2008; 13(1): 46-68
39. Zwickey RE, Peck HM, Bagdon WJ et al: Preclinical toxicological studies of CD and combinations of carbidopa and LD. Toxicol Appl Pharmacol, 1974; 29(2): 181-195
40. th October, 2008
41. Pierce JD, Jegathesan J, Levant B et al: Detection of dopamine receptor subtypes in the rat diaphragm. Heart Lung, 2007; 36(1): 58-63
42. Pierce JD, Goodyear-Bruch C, Hall S et al: Dopamine alleviation of diaphragm contractile dysfunction and reduction of deoxyribonucleic acid damage in rats. Heart Lung, 2008; 37(2): 132-143
43. Pierce JD, Clancy RL, Smith-Blair N, Kraft R: Treatment and prevention of diaphragm fatigue using low-dose dopamine. Biol Res Nurs, 2002; 3(3): 140-149
44. Pierce JD, Goodyear-Bruch C, Hall S, Clancy RL: Effect of dopamine on rat diaphragm apoptosis and muscle performance. Exp Physiol, 2006; 91(4): 731-740 (Pubitemid 43944644)
45. Collet F, Féve B, Frisdal E et al: Pharmacological and molecular characterisation of beta-adrenoceptors in adult rat diaphragm muscle. Respir Physiol, 1998; 112(1): 1-12 (Pubitemid 28274497)
46. van der Heijden HF, Heunks LM, Folgering H et al: Beta2-adrenoceptor agonists reduce the decline of rat diaphragm twitch force during severe hypoxia. Am J Physiol, 1999; 276(3 Pt 1): L474-80
47. Perry E, Martin-Ruiz C, Lee M et al: Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol, 2000; 393: 215-222 (Pubitemid 30193419)
48. Nordberg A: Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry, 2001; 49: 200-210 (Pubitemid 32178429)
49. Pereira EFR, Hilmas C, Santos MD et al: Unconventional ligands and modulators of nicotinic receptors. J Neurobiol, 2002; 53: 479-500 (Pubitemid 35375580)
50. Doody RS: Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry, 2003; 64: 11-17 (Pubitemid 37040373)
51. Willmore CB, Bespalov AY, Beardsley PM: Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate leverpress counts. Pharmacol Biochem Behav, 2001; 69: 493-502
52. Schugens MM, Egerter R, Daum I et al: The NMDA antagonist impairs classical eyeblink conditioning in humans. Neurosci Lett, 1997; 224: 57-60 (Pubitemid 27112869)
53. Janssens JP, Pache JC, Nicod LP: Physiological changes in respiratory function associated with ageing. European Respiratory Journal, 2001; 13(1): 197-205
54. Pride NB: Ageing and changes in lung mechanics Eur Respir J, 2005; 26: 563-565